A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Fatty Liver Disease Market on the basis of Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor), By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer), By Region (North America, Europe, Asia Pacific and ROW) and By Country (U.S., Canada , U.K., France, Germany, China, Japan, India, Brazil, South Africa and Saudi Arabia). Link http://azothanalytics.com/report/healthcare-pharma/global-fatty-liver-disease-drugs-market-by-type-ald-nafld-by-stages-of-ald-and-nafld-by-region-by-country-opportunities-and-forecast-2017-2022-r12115

1. Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages
of ALD and NAFLD, By Region, By Country: Opportunities and Forecast
(2017-2022)
• By Type- ALD and NAFLD
• ALD Stages - Alcoholic Steatosis and Alcoholic
Steatohepatitis
• NAFLD Stages - Non Alcoholic Steatosis and NASH
• By Region- North America, Europe, Asia Pacific and
ROW
• By Country - United States, Canada, United Kingdom,
Germany, France, India, Japan, China, Saudi Arabia,
South Africa, Brazil.
July 2017

2.  Fatty Liver Disease Market – By
Value (2012-2022)
 Breakdown-By Type (2012-2021)
• ALD
• NAFLD
 Breakdown –By NAFLD Stages (2012-
2022): (Steatosis , NASH)
 Breakdown –By ALD Stages (2012-
2022): (Steatosis, Alcohol Hepatitis)
 Breakdown by ALD drugs(2012-
2022): (Opoid Antagonist
,Glucocorticoid, Pentoxifyline,
Antioxidants, Granulocyte colony
stimulating factor)
 Breakdown By NAFLD Drug(2012-
2022) : (Antioxidants
Thiazolidinedione, Biguanides,
Hypolipidemic Agents, FXR receptor
agonist, Elafibranoer)
Global Coverage Regional Coverage
Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities
and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)
 Fatty Liver Disease Market - By
Value (2012-2016)
 Fatty Liver Disease Market – By
Value (2017-2022)
 Fatty Liver Disease Market – By
Type (2012-2022)
 Fatty Liver Disease Market –By
ALD Drugs ( 2012-2022)
 Fatty Liver Disease Market- By
NAFLD Drug
 North America
 Europe
 Asia Pacific
 ROW
Country Coverage
 Fatty Liver Disease Market : By
Value (2012-2022)
 Fatty Liver Disease Market : By
Type , By Value (2012-2022)
 U.S.
 Canada
 Germany
 France
 U.K.
 China
 Japan
 India
 Brazil
 South Africa
 South Arabia
Company Coverage
 Product Benchmarking
 Sales
 Business Overview
 Product Launches & Recent
Approvals
 Merger & Acquisition
 Pfizer
 Conatus
 Novartis
 Intercept pharmaceuticals
 Allergan
 Immuron
 Takeda
 Gilead sciences
 Genfitt
 g
 Global Coverage
 Regional Coverage
 Country Coverage
 Scope of the Study
 By Type
 By NAFLD Stages
 By ALD Stages
 By Type of Drugs
 Region (North America, Europe, APAC and ROW )
 Country (U.S., Canada, China, Japan, India , Germany, France,
United Kingdom, Saudi Arabia, South Africa, Brazil,)
 Product Benchmarking
 Sales
 Business Overview
 Product Launches & Recent
Approvals
 Merger & Acquisition
2

3. Table of Content
S. No Particulars Page No.
1. Research Methodology 22
2. Executive Summary 23
3. Strategic Recommendation 24
3.1 Focus on Asia Region 25
3.2 Focus on drug development for NASH and Alcohol Hepatitis 26
3.3 Focus on early Stage detection of Alcohol and Non Alcoholic Steatosis 27
4. Fatty Liver Market Outlook 28
5. Global Fatty Liver Disease Market: Growth and Forecast 36
5.1 By Value (2012-2016) 37
5.2 By Value (2017-2022) 38
6 Global Fatty Liver Disease –By Type 39
6.1 Global Fatty Liver Disease Market -By Type (Alcoholic Fatty Liver Disease (ALD), Non Alcoholic Fatty Liver
Disease (NAFLD)): Breakdown(%)
39
6.1.1 Global Fatty Liver Disease Market-By Type,2016 (%) 40
6.1.2 Global Fatty Liver Disease Market-By Type,2022 (%) 41
6.2 Global Fatty Liver Disease –By Type, By Value 42
6.2.1 Global Alcoholic Fatty Liver Disease Market 42
6.2.1.1 By Value (2012-2022) 42
3

4. Table of Content
S. No Particulars Page No.
6.2.2 Global Non Alcoholic Fatty Liver Disease Market 44
6.2.2.1 By Value (2012-2022) 44
7. Global Alcoholic Fatty Liver Disease Market –By Stages 47
7.1 Global Alcoholic Fatty Liver Disease Market -By Stages (Alcoholic Steatosis and Alcoholic
Steatohepatitis): Breakdown(%)
47
7.1.1 Global Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%) 48
7.1.2 Global Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%) 49
7.2 Global Alcoholic Fatty Liver Disease Market -By Stages, By Value 50
7.2.1 Global Alcoholic Steatosis Market 50
7.2.1.1 By Value (2012-2022) 50
7.2.2 Global Alcoholic Steatohepatitis Market 52
7.2.2.1 By Value (2012-2022) 52
8. Global Non Alcoholic Fatty Liver Disease Market–By Stages 54
8.1 Global Non Alcoholic Fatty Liver Disease Market -By Stages (Non Alcoholic Steatosis and Non Alcoholic
Steatohepatitis ) : Breakdown(%)
54
8.1.1 Global Non Alcoholic Fatty Liver Disease Market -By Stages , 2016(%) 55
8.2.1 Global Non Alcoholic Fatty Liver Disease Market -By Stages , 2022 (%) 56
4

5. Table of Content
S. No Particulars Page No.
8.2 Global Non Alcoholic Fatty Liver Disease Market -By Stages , By Value 57
8.2.1 Global Non Alcoholic Steatosis Market 57
8.2.1.1 By Value (2012-2022) 57
8.2.2 Global Non Alcoholic Steatohepatitis Market 58
8.2.2.1 By Value (2012-2022) 58
9. Global Alcoholic Fatty Liver Disease Market –By Drugs 61
9.1 Global Alcoholic Fatty Liver Disease Market -By Drugs (Opoid Antagonist, Glucocorticoid, Pentoxifyline,
Antioxidants, Granulocyte colony stimulating factor) : Breakdown(%)
61
9.1.1 Global Alcoholic Fatty Liver Disease Market -By Drugs , 2016(%) 62
9.1.2 Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2022 (%) 63
9.2 Global Alcoholic Fatty Liver Disease Market -By Drugs , By Value 64
9.2.1 Global Opioid Antagonist Drug Market 64
By Value (2012-2022) 64
9.2.2 Global Pentoxifylline Drug Market 66
By Value (2012-2022) 66
9.2.3 Global Glucocorticoid Drug Market 67
By Value (2012-2022) 67
5

6. Table of Content
S. No Particulars Page No.
9.2.4 Global Antioxidants Drug market 69
9.2.4.1 By Value (2012-2022) 69
9.2.5 Global Granulocyte colony stimulating factor Drug Market 71
9.2.5.1 By Value (2012-2022) 71
10. Global Non Alcoholic Fatty Liver Disease Market –By Drugs 73
10.1 Global Non Alcoholic Fatty Liver Disease Market -By Drugs (Antioxidants, Thiazolidinedione,
Biguanides, Lipid Lowering Agents, FXR Receptor Agonist, Elafibranor ) : Breakdown(%)
73
10.1.1 Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2016(%) 74
10.2.1 Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2022 (%) 75
10.2 Global Non Alcoholic Fatty Liver Disease Market -By Drugs , By Value 76
10.2.1 Global Antioxidants Drug Market 76
10.2.1.1 By Value (2012-2022) 76
10.2.2 Global Thiazolidinedione Drug Market 78
10.2.2.1 By Value (2012-2022) 78
10.2.3 Global Biguanides Drug Market 80
10.2.3.1 By Value (2012-2022) 80
6

7. Table of Content
S. No Particulars Page No.
10.2.4 Global Hypolipidemic Agents Drug market 82
10.2.4.1 By Value (2012-2022) 82
10.2.5 Global FXR Receptor Agonist Drug Market 84
10.2.5.1 By Value (2012-2022) 84
10.2.6 Global Elafibranor Drug Market 86
10.2.6.1 By Value (2012-2022) 86
11. Global Fatty Liver Disease Market – Pipeline Analysis (By developer, Phase and indication) 88
12. Global Fatty Liver Disease Market – Regional Analysis 93
12.1 Global Fatty Liver Disease Market -By Regional : Breakdown(%) 93
12.1.1 Global Fatty Liver Disease Market -By Region, 2016(%) 94
12.1.2 Global Fatty Liver Disease Market -By Region, 2022 (%) 95
13. North America Fatty liver Disease Market 96
13.1 By Value (2012-2022) 97
13.2 North America Fatty liver Disease Market – By Type , By Value 100
13.3 North America Fatty liver Disease Market – By ALD Drug , By Value 102
7

8. Table of Content
S. No Particulars Page No.
13.4 North America Fatty liver Disease Market – By NAFLD Drug , By Value 104
14. North America Fatty Liver Disease Market –By Country Analysis 105
14.1 North America Fatty Liver Disease Market –By Country ,2012-2016(%) 106
14.2 North America Fatty Liver Disease Market –By Country ,2017E-2022F(%) 106
14.3 United States Fatty Liver Disease Market – By Value(2012-2022) 107
14.3.1 United States Fatty Liver Disease Market By Type, By Value 109
14.4 Canada Fatty Liver Disease Market – By Value(2012-2022) 110
14.4.1 Canada Fatty Liver Disease Market By Type, By Value 111
15. Asia Pacific Fatty liver Disease Market 113
15.1 By Value (2012-2022) 114
15.2 Asia Pacific Fatty liver Disease Market – By Type , By Value 117
15.3 Asia Pacific Fatty liver Disease Market – By ALD Drug , By Value 119
15.4 Asia Pacific Fatty liver Disease Market – By NAFLD Drug , By Value 121
16. Asia Pacific Fatty Liver Disease Market –By Country Analysis 122
16.1 Asia Pacific Fatty Liver Disease Market –By Country ,2012-2016(%) 123
16.2 Asia Pacific Fatty Liver Disease Market –By Country ,2017E-2022F(%) 123
8

9. Table of Content
S. No Particulars Page No.
16.3 India Fatty Liver Disease Market – By Value(2012-2022) 124
16.3.1 India Fatty Liver Disease Market By Type, By Value 126
16.4 China Fatty Liver Disease Market – By Value(2012-2022) 127
16.5 Japan Fatty Liver Disease Market – By Value(2012-2022) 129
16.5.1 Japan Fatty Liver Disease Market By Type, By Value 130
16.6 Rest of Asia Fatty Liver Disease Market-By Value(2012-2022) 131
17. Europe Pacific Fatty liver Disease Market 132
17.1 By Value (2012-2022) 133
17.2 Europe Fatty liver Disease Market – By Type , By Value 137
17.3 Europe Fatty liver Disease Market – By ALD Drug , By Value 139
17.4 Europe Fatty liver Disease Market – By NAFLD Drug , By Value 141
18. Europe Fatty Liver Disease Market –By Country Analysis 142
18.1 Europe Fatty Liver Disease Market –By Country ,2012-2016(%) 143
18.2 Europe Fatty Liver Disease Market –By Country ,2017E-2022F(%) 143
9

10. Table of Content
S. No Particulars Page No.
18.3 United Kingdom Fatty Liver Disease Market – By Value(2012-2022) 144
18.3.1 United Kingdom Fatty Liver Disease Market By Type, By Value 145
18.4 Germany Fatty Liver Disease Market – By Value(2012-2022) 147
18.4.1 Germany Fatty Liver Disease Market By Type, By Value 149
18.5 France Fatty Liver Disease Market – By Value(2012-2022) 150
18.5.1 France Fatty Liver Disease Market By Type, By Value 151
18.6 Rest of Europe Fatty Liver Disease Market-By Value(2012-2022) 152
19. Rest of World Fatty liver Disease Market 153
19.1 By Value (2012-2022) 154
19.2 Rest of World Fatty liver Disease Market – By Type , By Value 156
19.3 Rest of World Fatty liver Disease Market – By ALD Drug , By Value 158
19.4 Rest of World Fatty liver Disease Market – By NAFLD Drug , By Value 160
20. Rest of World Fatty Liver Disease Market –By Country Analysis 161
20.1 Rest of World Fatty Liver Disease Market –By Country ,2012-2016(%) 162
20.2 Rest of World Fatty Liver Disease Market –By Country ,2017E-2022F(%) 162
10

11. Table of Content
S. No Particulars Page No.
20.3 Saudi Arabia Fatty Liver Disease Market – By Value(2012-2022) 163
20.3.1 Saudi Arabia Fatty Liver Disease Market By Type, By Value 164
20.4 South Africa Fatty Liver Disease Market – By Value(2012-2022) 166
20.4.1 South Africa Fatty Liver Disease Market By Type, By Value 168
20.5 Brazil Fatty Liver Disease Market – By Value(2012-2022) 169
20.5.1 Brazil Fatty Liver Disease Market By Type, By Value 170
20.6 Others Fatty Liver Disease Market-By Value(2012-2022) 171
21. Market Dynamics 172
21.1 Drivers 173
21.2 Challenges 177
22. Market Trends 180
23. Policy and Regulations 182
24. Porter Five Force 190
25. SWOT Analysis 192
26. Company Profiling 194
11

12. Table of Content
S. No Particulars Page No.
26.1 Pfizer 195
26.2 Conatus Pharmaceuticals 197
26.3 Novartis 198
26.4 Intercept Pharmaceuticals 200
26.5 Allergan 201
26.6 Immuron 202
26.7 Takeda 203
26.8 Gilead Sciences 205
26.9 Genfit 207
27. About Us 208
12

13. List of Figures
Figure No. Figure Title Page No.
Figure 1: History of Fatty Liver Disease 31
Figure 2: Therapeutic Algorithm for Management of Alcoholic Hepatitis 32
Figure 3: Treatment Algorithm of NAFLD 35
Figure 4: Global Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Million) 37
Figure 5: Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million) 38
Figure 6: Global Fatty Liver Disease Market Size, By Type, 2016 (%) 40
Figure 7: Global Fatty Liver Disease Market Size, By Type, 2022F (%) 41
Figure 8: Global Alcoholic Fatty liver Market Service Market, By Value, 2012-2016 (USD Billion) 42
Figure 9: Global Alcoholic Fatty liver Market Service Market, By Value, Forecast, 2017E-2022F (USD Billion) 42
Figure 10: Beer Consumption , Billion Liters , 2014 43
Figure 11: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, 2012-2016 (USD Billion) 44
Figure 12: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion) 44
Figure 13: Global Diabetic Population, By Region, 2015 (Million) 46
Figure 14: Global Alcoholic Liver Disease Market Size, By Stage , 2016 (%) 48
Figure 15: Global Alcoholic liver Disease Market Size, By Type, 2022F (%) 49
Figure 16: Global Alcoholic Steatosis Treatment , By Value, 2012-2016 (USD Billion) 50
Figure 17: Global Alcoholic Steatosis Treatment, By Value, Forecast, 2017E-2022F (USD Billion) 50
Figure 18: World Alcohol Consumption , Liters per Capita, 2014-2016 51
Figure 19: Global Alcoholic Staetohepatitis Market, By Value, 2012-2016 (USD Billion) 52
13

14. List of Figures
Figure No. Figure Title Page No.
Figure 20: Global Alcoholic Staetohepatitis Market, By Value, Forecast, 2017E-2022F (USD Billion) 52
Figure 21: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%) 55
Figure 22: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2022F (%) 56
Figure 23: Global Non Alcoholic Steatosis Treatment Market, By Value, 2012-2016 (USD Billion) 57
Figure 24: Global Non Alcoholic Steatosis Treatment Market, By Value, Forecast, 2017E-2022F(USD Billion) 57
Figure 25: Global NASH Market, By Value, 2012-2016 (USD Billion) 58
Figure 26: Global NASH Market, By Value, Forecast, 2017E-2022F (USD Billion) 58
Figure 27: Global Alcoholic Fatty Liver Market Size, By Drug, 2016 (%) 62
Figure 28: Global In-flight Catering Service Market Size, By Airline Type, 2022F (%) 63
Figure 29: Global Opioid Antagonist Drug Market, By Value, 2012-2016 (USD Billion) 64
Figure 30: Global Opioid Antagonist Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 64
Figure 31: Global Pentoxifylline Drug Market, By Value, 2012-2016 (USD Billion) 66
Figure 32: Global Pentoxifylline Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 66
Figure 33: Global Glucocoticoid Drug Market, By Value, 2012-2016 (USD Billion) 67
Figure 34: Global Glucocorticoid Drug Market, By Value Forecast, 2017E-2022F(USD Billion) 67
Figure 35: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion) 69
Figure 36: Global Antioxidants Drug Market, By Value, , Forecast, 2017E-2022F(USD Billion) 69
Figure 37: Global Granulocyte Colony Stimulating Factor Drug Market, By Value, 2012-2016 (USD Billion) 71
Figure 38: Global Granulocyte Colony Stimulating Factor Drug Market , By Value, Forecast, 2017E-2022F(USD Billion) 71
Figure 39: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2016 (%) 74
14

15. List of Figures
Figure No. Figure Title Page No.
Figure 40: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2022F (%) 75
Figure 41: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion) 76
Figure 42: Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022 (USD Billion) 76
Figure 43: Global Thiazolidinedione Drug Market, By Value, 2012-2016 (USD Billion) 78
Figure 44: Global Thiazolidinedione Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 78
Figure 45: Global Biguandies Drug Market, By Value, 2012-2016 (USD Billion) 80
Figure 46: Global Biguandies Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 80
Figure 47: Global Hypolipidemic Drug Market, By Value, 2012-2016 (USD Billion) 82
Figure 48: Global Hypolipidemic Drug Market , By Value, Forecast, 2017E-2022F(USD Billion) 82
Figure 49: Global FXR Receptor Agonist Drug Market, By Value, 2012-2016 (USD Billion) 84
Figure 50: Global FXR Receptor Agonist Drug Market , By Value, Forecast, 2017E-2022F (USD Billion) 84
Figure 51: Global Elafibranor Drug Market, By Value, 2012-2016 (USD Billion) 86
Figure 52: Global Elafibranor Drug Market , By Value, Forecast, 2017E-2022F (USD Billion) 86
Figure 53: Global Fatty Liver Disease Market Size and Share, By Region, 2016 94
Figure 54: Global Fatty Liver Disease Market Size and Share, By Segments, 2022F 95
Figure 55: North America Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 97
Figure 56: North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 97
Figure 57: North America Healthcare Expenditure, 2011-2014 (% of GDP) 98
Figure 58: North America Population Age 15-64 2015 (% of Total) 98
Figure 59: North America Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 100
Figure 60: North America Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion) 102
15

16. List of Figures
Figure No. Figure Title Page No.
Figure 61: North America Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion) 104
Figure 62: North America Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total) 106
Figure 63: North America Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total) 106
Figure 64: United States Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 107
Figure 65: United States Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 107
Figure 66: Percentage of United states adults who had at least one heavy drinking day,2011-2015 108
Figure 67: United States Alcohol Liters Per Capita Consumption, 2011-2015 108
Figure 68: United States Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 109
Figure 69: CanadaFatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 110
Figure 70: Canada Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 110
Figure 71: Canada Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 111
Figure 72: Canada Alcohol Liters Per Capita Consumption, 2011-2015 112
Figure 73: Prevalence of Obese and overweight Population , By Age,2014(% ) 112
Figure 74: Asia Pacific Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 114
Figure 75: Asia PacificFatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 114
Figure 76: Obesity Prevalence in Asian Countries, 2014 (%) 115
Figure 77: Asia Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 117
Figure 78: Asia Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion) 119
Figure 79: Asia Pacific Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion) 121
Figure 80: Asia Pacific Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total) 123
16

17. List of Figures
Figure No. Figure Title Page No.
Figure 81: Asia Pacific Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total) 123
Figure 82: India Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 124
Figure 83: India Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 124
Figure 84: Percentage of United states adults who had at least one heavy drinking day, 2011-2015 125
Figure 85: India Alcohol Liter per capita Consumptions, 2015-2016 125
Figure 86: India Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 126
Figure 87: China Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 127
Figure 88: China Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 127
Figure 89: Health expenditure in China,2011-2015 (USD Billion) 128
Figure 90: China Alcohol Liter per capita Consumptions,2015-2016 128
Figure 91: Japan Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 129
Figure 92: Japan Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 129
Figure 93: Japan Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 130
Figure 94: Rest of Asia Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 131
Figure 95: Rest of Asia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 131
Figure 96: Europe Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 133
Figure 97: Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 133
Figure 98: Europe Diabetes Prevalence, By Country, 2015 (% of Population Aged 20 to 79) 134
Figure 99: EU Health Expenditure Per Capita, 2011-2014 (USD) 135
Figure 100: Breakdown of Total Health Expenditure in Europe (%) 135
17

18. List of Figures
Figure No. Figure Title Page No.
Figure 101: Europe Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 137
Figure 102: Europe Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion) 139
Figure 103: Europe Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion) 141
Figure 104: Europe Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total) 143
Figure 105: Europe Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total) 143
Figure 106: United Kingdom Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 144
Figure 107: United Kingdom Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 144
Figure 108: United Kingdom Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 145
Figure 109: Alcohol Related Disease Death, 2015 146
Figure 110: Diabetes Prevalence in U.K. 2015 146
Figure 111: Five Day Drinking Prevalence By Age, (%), 2014-2015 146
Figure 112: Germany Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 147
Figure 113: Germany Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 147
Figure 114: Private Healthcare Spending in Germany, US Dollar/capita 2011 to 2015 148
Figure 115: Diabetes Prevalence in 55-74 age people in Germany, Forecast 2030F. 148
Figure 116: Alcohol Consumption per capita ,2012-2016 (liter) in Germany 148
Figure 117: Germany Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Million) 149
Figure 118: France Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 150
Figure 119: France Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 150
Figure 120: France Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Million) 151
18

19. List of Figures
Figure No. Figure Title Page No.
Figure 121: Rest Of Europe Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 152
Figure 122: Rest of Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 152
Figure 123: Rest of World Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 154
Figure 124: Rest of World Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 154
Figure 125: Rest of World Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 156
Figure 126: Rest of World Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 158
Figure 127: Rest of world Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion) 160
Figure 128: Rest of World Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total) 162
Figure 129: Rest of World Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total) 162
Figure 130: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 163
Figure 131: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 163
Figure 132: Saudi Arabia Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 164
Figure 133: Saudi Arabia Prevalence of Obesity Forecast 2022 (%) 165
Figure 134: South Africa Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 166
Figure 135: South Africa Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 166
Figure 136: South Africa Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 168
Figure 137: Brazil Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 169
Figure 138: Brazil Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 169
Figure 139: Brazil Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 170
Figure 140: Others Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 171
19

20. List of Figures
Figure No. Figure Title Page No.
Figure 141: Others Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 171
Figure 142: Pfizer Segmental Breakup, 2016(%) 196
Figure 143: Pfizer Sales, By Region, 2016 (%) 196
Figure 144: Novartis Sales, By Segment 2015 (%) 199
Figure 145: Novartis Sales, By Region,2015 (%) 199
Figure 146: Novartis Pharmaceuticals Sales, By Franchise, 2015 (%) 199
Figure 147: Takeda Segmental Breakup 204
Figure 148: Takeda Revenue, 2013-2016 (USD Million) 204
Figure 149: Gilead Sciences Product Sales, 2016 (%) 206
Figure 150: Gilead Sciences HCV Product Sales, 2014-2016 (USD Billion) 206
20

21. List of Tables
Table No. Table Title Page No.
Table A: Causes of NAFLD Infection 33
Table B: Quantity of Alcohol in Standard Drink 51
Table C: Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication 89
Table D: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication 90
Table E: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication 91
Table F: NASH Multi Therapy Treatment Market Analysis, By Drug, Developer, Phase, Indication, Status 92
21

22. Research Methodology
Research Definition
Global Fatty Liver Disease Treatment Market Report comprises of the study of various aspects of Fatty Liver
Market and forecast until 2022. Global Fatty Liver Disease Treatment Market has been segmented on basis of
Types(Alcoholic and Non Alcoholic Fatty Liver); Alcoholic Fatty Liver By Stages (Alcoholic Steatosis and
Alcoholic Steatohepatitis ), Non Alcoholic Fatty Liver Stages By Stages (Alcoholic Steatosis and Non Alcoholic
Steatohepatitis), By Region (North America, Europe, APAC, Middle East and ROW) and By Country (U.S.,
Canada, Germany, Russia, United Kingdom, China, India, Japan, Brazil, Mexico, Saudi Arabia, South Africa and
UAE)
Data Analysis and Interpretation
Our historic market trend has been figured out by various paid databases which was further triangulated with
inputs and insights from industry experts, companies and stakeholders, through primary research
(manufacturers, marketing managers, others). Back-of-the-Envelope calculation for the market estimation has
been made through proper understanding of the market as well as future business strategies of the companies
operating in the market. The Report has covered only two stages drug treatment for Alcoholic and Non
alcoholic fatty liver.
Azoth Analytics has conducted quantitative as well as qualitative research to gather market insights such as market sizing, market
segmentation, recent trends and developments and competitive landscape. Our team has conducted extensive primary surveys by
reaching out industry experts across the value chain of the global orthopeadic market.
Companies Contacted: St Stephen Hospital Delhi
22

23. Global Fatty Liver Disease Market Overview
• .
Source: Azoth Analytics Estimates
Figure : Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million)
2017E 2018F 2019F 2020F 2021F 2022F
CAGR: xxxx%
Global Fatty liver Disease market in the forecasted period will witness rapid growth owing to
several NASH Drug expected to enter the market in forecasted period.
Xxxx
Xxxx
Xxxx
Xxxx
Xxxx
xxxx
23

24. Global Non Alcoholic Liver Disease Market-By Stages
Figure : Global Non Alcoholic Liver Disease
Treatment Market Size, By Type, 2016 (%)
NASH treatment held the majority market share of approximately 81.67%, by value, in the year 2016.
Source: Azoth Analytics Estimates
Key Drivers
Non Alcoholic
Steatosis
Non Alcoholic
Steatohepatitis
Xxxxx
xxxxx
Xxxxx
xxxxx
24

25. Global Heart Valve Repair Devices Market, By Value
• .
Source: Azoth Analytics Estimates
CAGR 2012-2015
xxxx%
CAGR 2016-2022
xxxx%
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
North America Fatty Liver Disease Market
Xxxx
Xxxx
Xxxx
Xxxx
xxxx
Figure : North America Fatty Liver Disease Market
Size, By Value, 2012-2016(USD Billion)
Figure : North America Fatty Liver Disease Market
Size, By Value, 2017E-2022F (USD Billion)
25

26. Source: Azoth Analytics Estimates
Figure 93: Japan Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)
CAGR 2012-2016
Alcoholic Fatty Liver Disease: xxxx%
Non Alcoholic Fatty Liver Disease : xxxx%
Japan Fatty Liver Disease Market, By Type
Xxxxx
Xxxxx
Xxxxx
xxxxx
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR 2017-2022
Alcoholic Fatty Liver Disease: xxxx%
Non Alcoholic Fatty Liver Disease : xxxx%
26

27. Source: Azoth Analytics Estimates
Figure : Europe Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
CAGR 2012-201
Antioxidants: xxxx%
Thiazlolidinedione: xxxx%
Biguandies: xxxx%
HypolipidemicAgents: xxxx%
FXR Receptor Agonist: xxxx%
Elafibranor: xxxx %
Europe Fatty Liver Disease Market, By NFALD Drug
Xxxx
Xxxx
Xxxx
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR 2017-2022
Antioxidants: xxxx%
Thiazlolidinedione: xxxx%
Biguandies: xxxx%
Hypolipidemic agents: xxxxx%
FXR Receptor Agonist: xxxxx%
Elafibranor: xxxx%
27

28. About Azoth Analytics Pvt Ltd.
Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy
services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food &
beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic
market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).
Related Reports:
Global Vitreoretinal Surgery Devices Market (By Product, By End User, By Region, By Country): Opportunities and Forecast (2016-2021)
– By Product (Vitrectomy Machines & Packs, Photocoagulation Surgery Devices, Illumination Devices, Others); By End User (Hospitals, Free Standing
Ambulatory Surgery Center); By Region (North America, Europe, APAC, ROW); By Country (US, Canada, Mexico, UK, Germany, France, Japan, China,
India, Brazil, South Africa)
Global Biomaterials Market (By Type, By Application, By Region): Opportunities and Forecasts (2016-2021) - (By Material Type – Polymer,
Ceramic, Metal; By Application - Orthopaedic, Cardiovascular, Plastic Surgery, Wound Care); By Region-North America, Europe, APAC, ROW; By Country –
US, UK, Germany, Italy, Japan, China, India; Key Players – Strategy, Financial Performance)
Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for
any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis
provided in the report are meant for customers’ internal use only and not for general publication or disclosure to third parties.
28